FN Media Group Presents Microsmallcap.com Market Commentary
New York, NY – August 19, 2021 – With the number of new COVID cases surging, fueled by a highly contagious Delta variant and only 50% of the US population having been vaccinated, the need for rapid testing and treatments is more important than ever. Perhaps even more alarming is the fact that the Centers for Disease Control and Prevention (CDC) attributes between 80% and 87% of all US COVID-19 cases in the last two weeks of July to the new Delta variant. As biotechnology companies like Cocrystal Pharma Inc. (NASDAQ:COCP) and Merck & Co. (NYSE:MRK) continue working to create antiviral treatments for COVID-19 and emerging variants and vaccine-makers like Moderna Inc. (NASDAQ:MRNA) boost production, it’s becoming increasingly clear that rapid test developers like Sixth Wave Innovations Inc. (OTCQB:SIXWF) (CSE:SIXW) and Co-Diagnostics Inc. (NASDAQ:CODX) will be instrumental in helping curb the ongoing spread of the virus.
The increase in cases and decrease in vaccine effectiveness should be of concern, since it indicates that the Delta variant has the potential to cause COVID-19 outbreaks, even in highly vaccinated populations, warranting the development of rapid testing.
Fortunately, Sixth Wave Innovations Inc. a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs) just announced that it has improved the sensitivity and capability of its leading-edge nanotechnology to detect the presence of the SARS-CoV-2 at levels below 1,000,000 virus particles/mL.
“Reaching sensitivity measurements of 1,000,000 virus particles/mL is a huge technical achievement,” says Dr. Michael Joyce, a virologist who carried out the research at the University of Alberta’s Li Ka Shing Institute of Virology. “At this level, infectious persons who are actively shedding the virus can be detected.”
This high level of sensitivity is crucial to detecting infectious patients, and an important clinical weapon in the struggle to control the global spread of the Covid pandemic.
This announcement comes on the heels of two prior critical milestones. On April 14, Sixth Wave Innovations Inc. successfully demonstrated colorimetric detection of SARS-CoV-2,its patent pending Accelerated Molecular Imprinted Polymers (AMIPs) technology. Then on June 10, the company successfully demonstrated the detection of the UK and the South African SARS-CoV-2 variants, using two independent techniques: a color-based sensor and independently verified on a Quartz Crystal Microbalance (QCM) based AMIP sensor.
Co-Diagnostics Inc. (NASDAQ:CODX) has also been making major advancements and recently announced the publication of a paper showing its Logix Smart
COVID-19 Test Kit was used to demonstrate that the SARS-CoV-2 virus can be detected in cancer tissue of coronavirus patients, even before symptoms occur.
Vaccine Development Against Variants Continues To Gather Momentum
On June 14, Cocrystal Pharma Inc. (NASDAQ:COCP) announced that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants. A third-party laboratory contracted by Cocrystal conducted in vitro studies evaluating the antiviral activity of CDI-45205 and its analogs and results showed it had excellent antiviral activity against both the United Kingdom and South Africa variants.
In a recent update, multinational pharmaceutical company Merck & Co. (NYSE:MRK) announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. The Phase 3 portion of the global MOVe-OUT trial is now underway and the company plans to initiate a clinical program to evaluate molnupiravir for post-exposure prophylaxis in the second half of 2021.
Moderna Inc. (NASDAQ:MRNA) also just announced the publication of new data on the durability of the Moderna COVID-19 vaccine in generating neutralizing antibodies against variants of concern. According to the paper, the majority of individuals vaccinated with the Moderna COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose. Furthermore, the study showed that after two doses of the Moderna COVID-19 vaccine, binding and neutralizing antibodies were generated against ancestral strains of the virus and against the variants of concern, Alpha, Beta, Gamma, Delta, Epsilon and Iota.
Going forward, all evidence points to an extended coexistence with COVID-19, meaning that precision testing for the virus – such as that demonstrated by Sixth Wave’s AMIPs technology – will remain critically important for the foreseeable future.
To learn more about Sixth Wave and the Accelerated Molecular Imprinted Polymers (AMIPs) technology, click here.
Disclaimer: Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Sixth Wave Innovations
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.
Media Contact:
FN Media Group, LLC
info@financialnewsmedia.com
+1(561)325-8757
Source: Microsmallcap.com
